December 20, 2013

Press release:

Mitsubishi Tanabe Pharma Corporation

Daiichi Sankyo Co., Ltd.

TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus

Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy

OSAKA and TOKYO, Japan, December 20, 2013---Mitsubishi Tanabe Pharma Corporation (hereafter, Mitsubishi Tanabe Pharma; President & CEO: Michihiro Tsuchiya) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo; President & Representative Director: Joji Nakayama) announced today that Mitsubishi Tanabe Phama has received approval of a partial change in indication for TENELIA® 20mg tablets (generic name: Teneligliptin hydrobromide hydrate) for the treatment of type 2 diabetes mellitus.

Based on the approval of the partial change, the indication of TENELIA® has changed to "type 2 diabetes mellitus" based on the "Guideline for Clinical Evaluation of Oral Hypoglycemic Agents", and TENELIA® is now available for combination therapy with existing oral hypoglycemic agents, such as biganides, α-glucosidase inhibitors, rapid-acting insulin secretagogues, and insulin preparations, as well as sulfonylureas and thiazolidines that had been approved for the combination.

TENELIA® is a DPP-4 (dipeptidyl peptidase-4) inhibitor created by Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo through their strategic alliance to contribute to the treatment of diabetes in Japan. TENELIA®, with its potent and sustained action, has been proven highly effective in lowering the postprandial blood glucose levels, as well as fasting blood glucose levels, through once-a-day administration.

By providing this new treatment option for type 2 diabetes mellitus, Mitsubishi Tanabe Pharma and Daiichi Sankyo hope to provide further support for patients who are combating this disease.

For further information, please contact:	
Mitsubishi Tanabe Pharma Corporation Corporate Communications Department TEL：+81-6-6205-5211	Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL：+81-3-6225-1126